Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a Site Co-Principal Investigator and therapist for an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder, and has served as a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, psilocybin-assisted treatment of treatment resistant depression, and earlier phase 2 and 3 trials of MDMA-assisted psychotherapy. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.
Dr. Ingmar Gorman is a co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. As a psychologist, he shares his expertise in empirically supported psychedelic treatments with his clients and trainees alike. Dr. Gorman received his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University. He simultaneously served as site co-principal investigator on an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and is currently a study therapist on the same study, as well as another FDA approved clinical trial of psilocybin for treatment resistant depression. Dr. Gorman has published on the topics of classic psychedelics, ketamine, MDMA, and Psychedelic Harm Reduction and Integration.
Jeffrey Guss, MD is a psychiatrist, psychoanalyst, and researcher with specializations in psychoanalytic therapy, addictions and psychedelic therapy. He was Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU School of Medicine’s study on psilocybin-assisted psychotherapy in the treatment of cancer related existential distress, which was published in Journal of Psychopharmacology, 2016. He currently is a study therapist in the NYU study on Psilocybin-Assisted treatment of Major Depressive Disorder, a collaborator with Yale University’s study on psilocybin-assisted therapy for Major Depressive Disorder and a study therapist with the MAPS study on treatment of Post Traumatic Stress Disorder with MDMA-Assisted Psychotherapy. Jeff is interested in the integration of psychedelic therapies with contemporary psychoanalytic theory and has published in Studies in Gender and Sexuality and Psychoanalysis, Culture and Society. He co-authored a paper on the influence of therapists’ first hand experience with psychedelics on psychedelic-assisted psychotherapy research in The Journal of Psychedelic Studies. He is an Instructor and Mentor with the California Institute of Integral Studies’ Center for Psychedelic Therapies. He maintains a private practice in New York City.
Casey Paleos, MD is a psychiatrist and researcher with over a decade of experience in the use of psychedelic medicines for the treatment of mental illness, dating back to his work, while still in residency training, as a study therapist in the landmark Psilocybin Cancer Anxiety Study at NYU, where Dr. Guss was one of his mentors. Since then, Dr. Paleos was Co-Principal Investigator in the NYU-Bellevue Ketamine for Depression Study and has been treating patients in his private practice with both ketamine infusion therapy and ketamine-assisted psychotherapy since 2016. Presently, he is a study therapist and Principal Investigator, alongside Dr. Gorman, in the MAPS-sponsored MDMA-Assisted Psychotherapy for PTSD Phase 3 Clinical Trial, serves as Scientific Director at Mindbloom, Inc., and is a co-founder of Nautilus Sanctuary, a non-profit psychedelic research and clinical institution based in New York City.
Dr. Alan Davis is an Assistant Professor of Social Work at Ohio State University and Adjunct Assistant Professor in the Center for Psychedelic and Consciousness Research at Johns Hopkins University. Dr. Davis’s clinical experience includes working with people diagnosed with trauma-based psychological problems and includes providing evidenced-based treatments such as motivational interviewing, acceptance and commitment therapy, and psilocybin-assisted psychotherapy. His research interests focus on helping those suffering with substance use and mental health problems and developing ways to conceptualize substance use and mental health problems through a strengths-based approach. He recently completed a clinical trial of psilocybin therapy for depression and current trials exploring psychedelic treatment for patients with co-occurring alcohol use disorder and depression and patients with anorexia. He examines topics related to naturalistic psychedelic use among several populations including people of color who have experienced racial trauma, Spanish-speaking people, and people who use novel psychedelics such as 5-MeO-DMT.
Kelan is an Associate Professor and Board Certified Psychiatric Pharmacist with outpatient behavioral health practice sites in San Francisco and Oakland. His research interests include adverse reactions and drug interactions related to psychiatric medications and psychedelic-assisted therapy. Dr Thomas is also a sub-investigator for the MAPS-sponsored MDMA pharmacokinetics clinical trial at UCSF.
Assistant Trainers are community role models in their practice of psychedelic harm reduction and integration. Having attended Fluence trainings and incorporated the material of into their professional lives they are present on a regular basis at our workshops to provide assistance with breakout groups, give feedback on role plays, lead contemplative practices or small bits of programming, participate in demonstrations, contribute ideas and experiences, and provide an example of how this workshop might facilitate the development of a new part of someone's career.
Johan Eriksson is a psychologist and therapist on his Sweden’s first clinical trial of psilocybin treatment for depression at Karolinska Institute in Stockholm, sponsored by Osmond Labs. He has a background in Cognitive Behavioral Therapy, Acceptance and Commitment Therapy (ACT), and Intensive Short-term Dynamic Psychotherapy (ISTDP). He works with clients for psychedelic preparation and integration, as well as general psychotherapy in private practice. In 2016 Johan co-founded the Swedish Network for Psychedelic Science (NPV), and in 2019 he arranged and participated in the first Psychedelics 101 and 102 in Sweden. Johan has also co-author a peer-reviewed paper on ACT and psychedelic-assisted psychotherapy. His web page is www.psykologiskintegration.se.
Dr. Joe Flanders is a Psychologist and the founder and managing partner of Mindspace Wellbeing in Montreal, where he works as a therapist, certified mindfulness teacher and trainer, and consultant to organizations. He is also an Assistant Professor (Professional) in the Psychology Department at McGill University. Joe is the co-director of the Psychedelic Harm Reduction and Integration (PHRI) Program at Mindspace.
Leah Gooch teaches yoga, meditation, writing, and art in order to help individuals approach a deeper awareness of their existence. After teaching art in New York City for eight years she facilitated the creation of a mural inside of Crossroads Detention Center in Brooklyn, completed by fifteen justice-involved youth. Leah is currently a teacher and Recreation Program Leader at a correctional facility. She facilitates public and private workshops and yoga lessons and is a reiki master practitioner. Her website is fourminutesaday.org - a reference to her initial commitment to meditate for (at least!) four minutes a day.
David Gumpel is an Integral Master Coach and a qualified teacher of Mindfulness-Based Stress Reduction (MBSR) through UMASS medical school. David is the co-founder of Access Mindfulness and a study coordinator for the MAPS sponsored MDMA-Assisted Psychotherapy for the treatment of post-traumatic stress study in NYC. He also is a site coordinator for the New York Psychiatric Institute’s Cognitive Behavioral Therapy Lab at Columbia University. As a coach, David teaches mindfulness to clients in private practice and to groups in corporate settings. Find him online at ebcpathways.com.
Jayne is a licensed Clinical Social Worker with 30 years of clinical experience and training. Non ordinary states of consciousness often offer clients extraordinary learning opportunities for deep and sustainable change, and Jayne offers support and integration guidance for those who are attracted to healing modalities such as plant medicine, ketamine, body centered therapies and breathwork. She is a MBSR teacher, experienced meditator, and co-founder of Access Mindfulness, a non-profit dedicated to bringing mindfulness to schools. She offers clinical services remotely and in person Midtown East, NYC and Woodstock, New York.
Dr. Xiaojue Hu is a psychiatrist based in New York City. She’s currently the Co-Investigator and a study therapist on a clinical trial investigating the impact of psilocybin on the treatment of major depression at the New York University School of Medicine. Xiaojue is also in private practice at an integrative mental health clinic, working with pioneering nutritional psychiatrist Drew Ramsey. She is trained in Focusing, a mind-body therapeutic approach, as well as psychedelic integration. Xiaojue is also interested in spirituality, women’s mental health, and cultural psychiatry, having worked as the leading psychiatrist at the Asian Bicultural Clinic at Gouverneur Health, an NYU-affiliated clinic providing care to the underserved.
Joseph McCowan, Psy.D, is a licensed clinical psychologist and psychotherapist, currently working in Los Angeles as a co-therapist in the MAPS sponsored Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD. He is an alumni of MAPS’ MDMA Therapy Training for Communities of Color, held in August 2019. Additionally, Joseph works with the California Center for Psychedelic Therapy where he provides Ketamine Assisted Psychotherapy (KAP) and Psychedelic Integration Therapy. Joseph is deeply passionate about furthering education and awareness of the healing benefits of psychedelics for communities of color and in working to improve mental health outcomes for historically underserved communities. Joseph received his undergraduate degree in psychology from the University of California, Santa Barbara, and his doctorate in clinical psychology from the Chicago School of Professional Psychology.
Rebecca is a licensed Clinical Social Worker and founder of Plant Parenthood, a digital and in-person community of parents who use psychedelics. At her private practice in Brooklyn, NY she works with creative professionals using mindfulness and experiential techniques to address depression, anxiety and life transitions. In addition, she works in the re-emerging clinical space of psychedelic harm reduction and integration, helping clients prepare for psychedelic experiences, incorporate insights or cope with challenges post-experience. Her experience includes Mindfulness-Based Stress Reduction, Mindfulness for Clinicians, Psychedelics 101 & 102, and Beyond Experience Psychedelic Integration Workshop.
Andrew is the Director of Programming and a mindfulness teacher at Mindspace Wellbeing in Montreal, where he oversees all group programming and teaches Mindfulness Based Stress Reduction. He is also the Co-Director of Mindspace’s Psychedelic Harm Reduction and Integration (PHRI) program where he provides harm reduction and integration services for clients and supports Mindspace’s growing team of therapists building their own competencies in psychedelic integration work. Prior to joining Mindspace he established a weekly integration group focused on exploring the relationship between psychedelics and meditation and mindfulness practices, and has also facilitated integration circles for the Montreal Psychedelic Society.
Michael is a psychologist based in Stockholm, Sweden. He is trained in the psychodynamic tradition, Acceptance and Commitment Therapy, and mindfulness-based interventions. He is a Mindfulness-Based Cognitive Therapy instructor, has worked with mediyoga, and teaches mindfulness meditation in his spare time. In 2016, he co-founded the Swedish Network for Psychedelic Science (NPV) and in 2019 he arranged and participated in the first Psychedelics 101 and 102, facilitated by Elizabeth Nielson and Ingmar Gorman, in Sweden. Michael was also co-investigator in a research study that examined the effects of oxytocin on non-ordinary states of consciousness.
Dr. Kelly Sykes is a child forensic psychologist and maintains a private practice in Brooklyn, New York. She works primarily with court referred families as a custody evaluator, parenting or family coordinator, or therapeutic supervisor. She also provides expert consultation and testimony in matters that concern parent-child contact problems, child sexual abuse evaluations, trauma & parenting, and adoption & termination of parental rights. Her work is heavily influenced by psychoanalysis and attachment theory. Kelly’s interest in psychedelic integration therapy evolved from years of working with court referred parents with histories of complex trauma, persistent mood disorders, and substance abuse problems. Noting that for some, talk therapies helped with insight but failed to inhibit endangering behavior or led to meaningful change such that they could parent their children. This sparked her interest in learning more about the role the brain plays in the chronicity of certain psychological conditions and the research on psychedelic treatments.
No. Our trainings do not include any administration of any psychedelic compounds. While we recognize that such experiences can be a valuable part of training for some professionals in certain situations, we believe they are neither necessary nor sufficient, and value a more general familiarity with alternative states of consciousness.
Depending on the compound there may be a legal avenue to do so either by participating in a research trial, receiving treatment (as a patient) with a currently available psychedelic (e.g. ketamine), or traveling abroad.
Some of our programs offer the option to purchase APA CE and/or CME certificate. You will need to check with your licensing board in your state to see if those credits are acceptable for your purposes.
Our intention is to keep our fees affordable for working mental health professionals. At most of our programs we reserve select number of spaces for a discounted rate for applicants whose presence would benefit the community for whom our fee would be a hardship. We prioritize providing scholarships to participants whose participation will enhance diversity among clinicians educated in this modality and/or the populations to which it is available. Applications will be accepted and scholarships awarded on a rolling basis, so please apply early. Where available, you will find a link to the application for a scholarship spot on the page for each training. Please note scholarships only apply to training fees and do not cover transportation, lodging, and meals.
We work with a variety of community partners to bring our trainings to their hometowns. Our programs can be open to the public or private for the members of your organization, and tailored to suit your community’s needs. If you would like to collaborate on holding a training locally, please email us and we’ll start the conversation.
Fluence does not provide any clinical services. If you are seeking a therapist who is trained in this area, please contact the Psychedelic Education & Continuing Care Program or search the therapist listings at psychedelic.support. Additionally you may find this guide to finding a therapist for psychedelic integration helpful.
To learn more about our cancellation policy, attendance policy, CE policy, contact and communication policy, as well as our disclaimer and waiver, please see our policy page.